Movement Alert｜Pfizer Intraday Rise 3.05% in Regular Trading, price target increases and recent FDA approval support sentiment

Market Focus

Oct 14

On October 14, Pfizer posted an Intraday Rise of 3.05% in Regular Trading, trading at $29.22 per share with turnover of $192 million.

The move was accompanied by a fresh round of analyst target price increases. JPMorgan recently raised its target price on Pfizer to $30 from $28, following Bank of America lifting its target to $29 from $27 and Scotiabank increasing its target to $33 from $30, reinforcing expectations for valuation recovery.

Recent company-specific developments also provided support. Earlier in October, the FDA approved Tukysa in combination with trastuzumab and pertuzumab for maintenance treatment of HER2-positive metastatic breast cancer in the first-line setting, adding a fundamental catalyst alongside the improving sell-side view.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1126221910"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126221910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126221910?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-14 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126221910","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pfizer Intraday Rise 3.05% in Regular Trading, price target increases and recent FDA approval support sentiment","media":"Market Focus","content":"<p><p>On October 14, Pfizer posted an Intraday Rise of 3.05% in Regular Trading, trading at $29.22 per share with turnover of $192 million.</p><p>The move was accompanied by a fresh round of analyst target price increases. JPMorgan recently raised its target price on Pfizer to $30 from $28, following Bank of America lifting its target to $29 from $27 and Scotiabank increasing its target to $33 from $30, reinforcing expectations for valuation recovery.</p><p>Recent company-specific developments also provided support. Earlier in October, the FDA approved Tukysa in combination with trastuzumab and pertuzumab for maintenance treatment of HER2-positive metastatic breast cancer in the first-line setting, adding a fundamental catalyst alongside the improving sell-side view.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pfizer Intraday Rise 3.05% in Regular Trading, price target increases and recent FDA approval support sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pfizer Intraday Rise 3.05% in Regular Trading, price target increases and recent FDA approval support sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-14 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 14, Pfizer posted an Intraday Rise of 3.05% in Regular Trading, trading at $29.22 per share with turnover of $192 million.</p><p>The move was accompanied by a fresh round of analyst target price increases. JPMorgan recently raised its target price on Pfizer to $30 from $28, following Bank of America lifting its target to $29 from $27 and Scotiabank increasing its target to $33 from $30, reinforcing expectations for valuation recovery.</p><p>Recent company-specific developments also provided support. Earlier in October, the FDA approved Tukysa in combination with trastuzumab and pertuzumab for maintenance treatment of HER2-positive metastatic breast cancer in the first-line setting, adding a fundamental catalyst alongside the improving sell-side view.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"","article_id":"1126221910","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126221910","pubTimestamp":1791986824,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 14, Pfizer posted an Intraday Rise of 3.05% in Regular Trading, trading at $29.22 per share with turnover of $192 million.The move was accompanied by a fresh round of analyst target price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"走势提醒|辉瑞常规交易盘中上涨3.05%，目标价上调和近期FDA批准支撑情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"On October 14, Pfizer posted an Intraday Rise of 3.05% in Regular Trading, trading at $29.22 per share with turnover of $192 million.The move was accompanied by a fresh round of analyst target price increases. JPMorgan recently raised its target price on Pfizer to $30 from $28, following Bank of America lifting its target to $29 from $27 and Scotiabank increasing its target to $33 from $30, reinforcing expectations for valuation recovery.Recent company-specific developments also provided support. Earlier in October, the FDA approved Tukysa in combination with trastuzumab and pertuzumab for maintenance treatment of HER2-positive metastatic breast cancer in the first-line setting, adding a fundamental catalyst alongside the improving sell-side view.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}